Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
October 24, 2024 09:15 ET
|
Cyclacel
CYCLACEL PHARMACEUTICALS ANNOUNCES THAT NASDAQ GRANTED AN EXTENSION TO REGAIN COMPLIANCE WITH THE EQUITY STANDARD RULE
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
August 28, 2024 14:48 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
August 06, 2024 09:26 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq’s $1.00 minimum bid price requirement.
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
May 24, 2024 16:30 ET
|
BIO-key International, Inc.
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq regarding untimely filing of its form 10-Q.
Evaxion Receives Nasdaq Notification
May 10, 2024 17:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Auddia Announces Closing of $2.3M PIPE to Eliminate Debt and Regain Nasdaq Compliance
April 29, 2024 08:00 ET
|
Auddia Inc.
BOULDER, CO, April 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), a developer of a proprietary AI platform for audio and...
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
April 22, 2024 16:30 ET
|
BIO-key International, Inc.
BIO-key International, Inc. Received Notice of Non-Compliance from Nasdaq regarding filing all required periodic financial reports with the SEC.
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 07, 2024 08:30 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
January 08, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
November 03, 2023 16:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...